Search

Your search keyword '"Mäenpää, J"' showing total 513 results
Start Over Author "Mäenpää, J"
513 results on '"Mäenpää, J"'

2. Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial

Author

Bogner, Gerhard, Marth, Christian, Petru, Edgar, Reinthaller, Alexander, Schauer, Christian, Sevelda, Paul, D’Hondt, Lionel, Vergote, Ignace, Vuylsteke, Peter, Hietanen, Sakari, Lindahl, Gabriel, Mäenpää, Johanna, Nøttrup, Trine Jakobi, Puistola, Ulla, Abadie-Lacourtoisie, Sophie, Alexandre, Jérôme, Berton-Rigaud, Dominique, Boissier, Emilie, Bourgeois, Hugues, Chevalier-Place, Annick, Combe, Pierre, Costan, Cristina, Dauba, Jérôme, De Cock, Laure, Desauw, Christophe, Despax, Raymond, Dohollou, Nadine, Dubot, Coraline, Fabbro, Michel, Favier, Laure, Floquet, Anne, Follana, Philippe, Tixidre, Claire Garnier, Garnier, Georges, Gladieff, Laurence, Grenier, Julien, Guillemet, Cécile, Hardy-Bessard, Anne-Claire, Joly, Florence, Kalbacher, Elsa, Kaminsky, Marie-Christine, Kurtz, Jean-Emmanuel, Largillier, Rémy, Lefeuvre-Plesse, Claudia, Lesoin, Anne, Levache, Charles Briac, L’Haridon, Tifenn, Lortholary, Alain, Lotz, Jean-Pierre, Medioni, Jacques, Meunier, Jérôme, Mousseau, Mirerille, Mouret-Reynier, Marie-Ange, Pautier, Patricia, Petit, Thierry, Provansal, Magali, Pujade-Lauraine, Eric, Raban, Nadia, Ray-Coquard, Isabelle, Rodrigues, Manuel, Selle, Frédéric, Sverdlin, Robert, Tazi, Youssef, You, Benoît, Aktas, Bahriye, Olaf Bauerschlag, Dirk, Beck, Thomas, Belau, Antje, Bronger, Holger, Buchholz, Stefan, Buderath, Paul, Burges, Alexander, Canzler, Ulrich, de Gregorio, Nikolaus, Denschlag, Dominik, Dieterich, Max, Eichbaum, Michael, El-Balat, Ahmed, Emons, Günter, Fasching, Peter, Feisel-Schwickardi, Gabriele, Frank, Matthias, Friedrich, Michael, Grischke, Eva-Maria, Gropp-Meier, Martina, Hanker, Lars, Hannig, Carla, Harter, Philipp, Hasenburg, Annette, Hellriegel, Martin, Herwig, Uwe, Heubner, Martin, Hulde, Joachim, Jackisch, Christian, Kögel, Matthias, Krieger, Peter, Kühn, Thorsten, Liebrich, Clemens, Lück, HansJoachim, Mallmann, Peter, Marmé, Frederik, Meier, Werner, Möbus, Voker, Mohamed, Omar Farag, Nestle-Krämling, Carolin, Neunhöffer, Tanja, Oskay-Özcelik, Gülten, Park-Simon, Tjoung-Won, Rautenberg, Beate, Rein, Daniel, Ruhwedel, Wencke, Runnebaum, Ingo, Sagasser, Jacqueline, Schmalfeldt, Barbara, Schneeweiss, Andreas, Schnelzer, Andreas, Scholz, Heinz, Sehouli, Jalid, Sperfeld, Antje, Steckkönig, Annette, Strauß, Hans-Georg, Tomé, Oliver, Treustedt, Jörn, Voß, Hermann, Wischnik, Arthur, Witteler, Ralf, Wöckel, Achim, Woeltjen, Hans-Heinrich, Zorr, Andreas, Bologna, Alessandra, Colombo, Nicoletta, Tognon, Germana, Cinieri, Saverio, Lorusso, Domenica, Mosconi, Anna Maria, Pignata, Sandro, Savarese, Antonella, Scambia, Giovanni, Sorio, Roberto, Zamagni, Claudio, Fujiwara, Keiichi, Fujiwara, Hiroyuki, Kobayashi, Hiroaki, Matsumoto, Takashi, Nagao, Shoji, Satoh, Toyomi, Yonemori, Kan, Yoshida, Hiroyuki, Bratos, Raquel, Caballero, Cristina, Garica, Yolanda, González-Martín, Antonio, Guerra-Alía, Eva Maria, Hernando, Susana, Herrero, Ana, Lainez, Nuria, Manso, Luis, Martin, Cristina, Murata, Eleonor, Ortega, Eugenia, Palacio, Isabel, Poveda, Andres, Romero, Ignacio, Rubio-Pérez, María Jesús, Harter, P., Marth, C., Mouret-Reynier, M.-A., Cropet, C., Lorusso, D., Guerra-Alía, E.M., Matsumoto, T., Vergote, I., Colombo, N., Mäenpää, J., Lebreton, C., de Gregorio, N., Mosconi, A.M., Rubio-Pérez, M.J., Bourgeois, H., Fasching, P.A., Cecere, S.C., Hardy-Bessard, A.-C., Denschlag, D., de Percin, S., Hanker, L., Favier, L., Bauerschlag, D., Desauw, C., Hillemanns, P., Largillier, R., Sehouli, J., Grenier, J., Pujade-Lauraine, E., and Ray-Coquard, I.

Published
2024
Full Text
View/download PDF

3. INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

Author

Colombo, N., Gadducci, A., Sehouli, J., Rulli, E., Mäenpää, J., Sessa, C., Montes, A., Ottevanger, N. B., Berger, R., Vergote, I., D’Incalci, M., Churruca Galaz, C., Chekerov, R., Nyvang, G. B., Riniker, S., Herbertson, R., Fossati, R., Barretina-Ginesta, M. P., Deryal, M., Mirza, M. R., Biagioli, E., Iglesias, M., Funari, G., Romeo, M., Tasca, G., Pardo, B., Tognon, G., Rubio-Pérez, M. J., DeCensi, A., De Giorgi, U., Zola, P., Benedetti Panici, P., Aglietta, M., Arcangeli, V., Zamagni, C., Bologna, A., Westermann, A., Heinzelmann-Schwarz, V., Tsibulak, I., Wimberger, P., and Poveda, A.

Published
2023
Full Text
View/download PDF

4. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

Author

Ray-Coquard, I., Leary, A., Pignata, S., Cropet, C., González-Martín, A., Marth, C., Nagao, S., Vergote, I., Colombo, N., Mäenpää, J., Selle, F., Sehouli, J., Lorusso, D., Guerra Alia, E.M., Bogner, G., Yoshida, H., Lefeuvre-Plesse, C., Buderath, P., Mosconi, A.M., Lortholary, A., Burges, A., Medioni, J., El-Balat, A., Rodrigues, M., Park-Simon, T.-W., Dubot, C., Denschlag, D., You, B., Pujade-Lauraine, E., and Harter, P.

Published
2023
Full Text
View/download PDF

5. PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial

Author

Loverix L., Vergote I., Busschaert P., Vanderstichele A., Venken T., Boeckx B., Harter P., Brems H., Van Nieuwenhuysen E., Pignata S., Baert T., Gonzalez-Martin A., Han S., Marth C., Neven P., Colombo N., Berteloot P., Mäenpää J., Olbrecht S., Laga T., Sablon E., Ray-Coquard I., Pujade-Lauraine E., Lambrechts D., Van Gorp T., Loverix, L, Vergote, I, Busschaert, P, Vanderstichele, A, Venken, T, Boeckx, B, Harter, P, Brems, H, Van Nieuwenhuysen, E, Pignata, S, Baert, T, Gonzalez-Martin, A, Han, S, Marth, C, Neven, P, Colombo, N, Berteloot, P, Mäenpää, J, Olbrecht, S, Laga, T, Sablon, E, Ray-Coquard, I, Pujade-Lauraine, E, Lambrechts, D, and Van Gorp, T

Subjects
Targeted therapy, Cancer Research, PARP inhibitor, Oncology, Ovarian cancer, HRD testing, Leuven HRD test
Abstract

Background: The PAOLA-1/ENGOT-ov25 trial showed improved progression-free (PFS) and overall survival (OS) in homologous recombination deficient (HRD) positive patients treated with olaparib, but not when HRD negative (HRD tested with MyChoice CDx PLUS [Myriad test]). Patients and methods: The academic Leuven HRD test consists of capture-based targeted sequencing of genome-wide single-nucleotide polymorphisms and coding exons of eight HR genes including BRCA1, BRCA2, and TP53. We compared the predictive value of the Leuven HRD versus Myriad HRD test for PFS and OS in the randomised PAOLA-1 trial. Results: 468 patients had left-over DNA after Myriad testing for Leuven HRD testing. Positive/negative/overall percent agreement for the Leuven versus Myriad HRD status was 95%/86%/91%, respectively. Tumours were HRD+ in 55% and 52%, respectively. In Leuven HRD+ patients, 5 years PFS (5yPFS) was 48.6% versus 20.3% (HR 0.431; 95% confidence intervals (CI) 0.312–0.595) for olaparib versus placebo, respectively (Myriad test 0.409; 95% CI 0.292–0.572). In Leuven HRD+/BRCAwt patients 5yPFS was 41.3% versus 12.6% (HR 0.497; 95% CI 0.316–0.783), and 43.6% versus 13.3% (HR 0.435; 95% CI 0.261–0.727) for the Myriad test. 5yOS was prolonged in the HRD+ subgroup with both tests 67.2% versus 54.4% (HR 0.663; 95% CI 0.442–0.995) for the Leuven test, and 68.0% versus 51.8% (HR 0.596 95% CI 0.393–0.904) for the Myriad test. HRD status was undetermined in 10.7% and 9.4% of the samples, respectively. Conclusions: A robust correlation between the Leuven HRD and Myriad test was observed. For HRD+ tumours, the academic Leuven HRD showed a similar difference in PFS and OS as the Myriad test.

Published
2023
Full Text
View/download PDF

7. PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial

Author

Loverix, L, Vergote, I, Busschaert, P, Vanderstichele, A, Venken, T, Boeckx, B, Harter, P, Brems, H, Van Nieuwenhuysen, E, Pignata, S, Baert, T, Gonzalez-Martin, A, Han, S, Marth, C, Neven, P, Colombo, N, Berteloot, P, Mäenpää, J, Olbrecht, S, Laga, T, Sablon, E, Ray-Coquard, I, Pujade-Lauraine, E, Lambrechts, D, Van Gorp, T, Loverix L., Vergote I., Busschaert P., Vanderstichele A., Venken T., Boeckx B., Harter P., Brems H., Van Nieuwenhuysen E., Pignata S., Baert T., Gonzalez-Martin A., Han S., Marth C., Neven P., Colombo N., Berteloot P., Mäenpää J., Olbrecht S., Laga T., Sablon E., Ray-Coquard I., Pujade-Lauraine E., Lambrechts D., Van Gorp T., Loverix, L, Vergote, I, Busschaert, P, Vanderstichele, A, Venken, T, Boeckx, B, Harter, P, Brems, H, Van Nieuwenhuysen, E, Pignata, S, Baert, T, Gonzalez-Martin, A, Han, S, Marth, C, Neven, P, Colombo, N, Berteloot, P, Mäenpää, J, Olbrecht, S, Laga, T, Sablon, E, Ray-Coquard, I, Pujade-Lauraine, E, Lambrechts, D, Van Gorp, T, Loverix L., Vergote I., Busschaert P., Vanderstichele A., Venken T., Boeckx B., Harter P., Brems H., Van Nieuwenhuysen E., Pignata S., Baert T., Gonzalez-Martin A., Han S., Marth C., Neven P., Colombo N., Berteloot P., Mäenpää J., Olbrecht S., Laga T., Sablon E., Ray-Coquard I., Pujade-Lauraine E., Lambrechts D., and Van Gorp T.

Abstract

Background: The PAOLA-1/ENGOT-ov25 trial showed improved progression-free (PFS) and overall survival (OS) in homologous recombination deficient (HRD) positive patients treated with olaparib, but not when HRD negative (HRD tested with MyChoice CDx PLUS [Myriad test]). Patients and methods: The academic Leuven HRD test consists of capture-based targeted sequencing of genome-wide single-nucleotide polymorphisms and coding exons of eight HR genes including BRCA1, BRCA2, and TP53. We compared the predictive value of the Leuven HRD versus Myriad HRD test for PFS and OS in the randomised PAOLA-1 trial. Results: 468 patients had left-over DNA after Myriad testing for Leuven HRD testing. Positive/negative/overall percent agreement for the Leuven versus Myriad HRD status was 95%/86%/91%, respectively. Tumours were HRD+ in 55% and 52%, respectively. In Leuven HRD+ patients, 5 years PFS (5yPFS) was 48.6% versus 20.3% (HR 0.431; 95% confidence intervals (CI) 0.312–0.595) for olaparib versus placebo, respectively (Myriad test 0.409; 95% CI 0.292–0.572). In Leuven HRD+/BRCAwt patients 5yPFS was 41.3% versus 12.6% (HR 0.497; 95% CI 0.316–0.783), and 43.6% versus 13.3% (HR 0.435; 95% CI 0.261–0.727) for the Myriad test. 5yOS was prolonged in the HRD+ subgroup with both tests 67.2% versus 54.4% (HR 0.663; 95% CI 0.442–0.995) for the Leuven test, and 68.0% versus 51.8% (HR 0.596 95% CI 0.393–0.904) for the Myriad test. HRD status was undetermined in 10.7% and 9.4% of the samples, respectively. Conclusions: A robust correlation between the Leuven HRD and Myriad test was observed. For HRD+ tumours, the academic Leuven HRD showed a similar difference in PFS and OS as the Myriad test.

Published
2023

10. INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

Author

INOVATYON study group, Colombo, N., Gadducci, A., Sehouli, J., Rulli, E., Mäenpää, J., Sessa, C., Montes, A., Ottevanger, N. B., Berger, R., Vergote, I., D'Incalci, M., Churruca Galaz, C., Chekerov, R., Nyvang, G. B., Riniker, S., Herbertson, R., Fossati, R., Barretina-Ginesta, M. P., Deryal, M., Mirza, M. R., Biagioli, E., Iglesias, M., Funari, G., Romeo, M., Tasca, G., Pardo, B., Tognon, G., Rubio-Pérez, M. J., DeCensi, A., De Giorgi, U., Zola, P., Benedetti Panici, P., Aglietta, M., Arcangeli, V., Zamagni, C., Bologna, A., Westermann, A., Heinzelmann-Schwarz, V., Tsibulak, I., Wimberger, P., Poveda, A., Tampere University, Clinical Medicine, Department of Gynaecology and Obstetrics, Colombo, N, Gadducci, A, Sehouli, J, Rulli, E, Mäenpää, J, Sessa, C, Montes, A, Ottevanger, N, Berger, R, Vergote, I, D'Incalci, M, Churruca Galaz, C, Chekerov, R, Nyvang, G, Riniker, S, Herbertson, R, Fossati, R, Barretina-Ginesta, M, Deryal, M, Mirza, M, Biagioli, E, Iglesias, M, Funari, G, Romeo, M, Tasca, G, Pardo, B, Tognon, G, Rubio-Pérez, M, Decensi, A, De Giorgi, U, Zola, P, Benedetti Panici, P, Aglietta, M, Arcangeli, V, Zamagni, C, Bologna, A, Westermann, A, Heinzelmann-Schwarz, V, Tsibulak, I, Wimberger, P, and Poveda, A

Subjects
Cancer Research, All institutes and research themes of the Radboud University Medical Center, Oncology, 3123 Gynaecology and paediatrics, 3122 Cancers, platinum-free interval, Women's cancers Radboud Institute for Health Sciences [Radboudumc 17]
Abstract

Background This trial investigated the hypothesis that the treatment with trabectedin/PLD (TP) to extend the platinum-free interval (TFIp) can improve overall survival (OS) in patients with recurrent ovarian cancer (OC). Methods Patients with OC (up to two previous platinum-based lines), with a TFIp of 6–12 months, were randomised to receive carboplatin/PLD (CP) or TP followed by platinum therapy at relapse. The primary endpoint was OS (HR: 0.75). Results The study enrolled 617 patients. The median TFIp was 8.3 months and 30.3% of patients had received two previous platinum lines. 74% and 73.9% of patients, respectively, received a subsequent therapy (ST) in the CP and TP arm; in the latter TP arm 87.2% of ST was platinum-based, as per protocol. The median OS was 21.4 for CP and 21.9 months for TP (HR 1.13; 95% CI: 0.94–1.35; p = 0.197). Grade 3–5 adverse reactions occurred in 37.1% of patients in the CP arm and 69.7% of patients in the TP arm, and the most frequent were neutropenia (22.8% CP, 39.5% TP), gastrointestinal (7.1% CP, 17.4% TP), hepatic (0.7% CP, 19.1% TP). Conclusions This study did not meet the primary endpoint. CP combination remains the standard for patients with recurrent OC and a 6–12 months TFIp; TP is an effective treatment in patients suffering from persistent platinum toxicities. Clinical trial registration ClinicalTrials.gov, number NCT01379989.

Published
2023

11. Operational risk management in high-mix, low-volume production

Author

Mäenpää, J. (Joonas)

Subjects
Tuotantotalous
Abstract

The objective of this Master’s thesis is to study operational risk management in High-Mix, Low-Volume production, with a focus on small and medium-sized enterprises. This objective is achieved through answering three research questions regarding previous literature, current state in a case company, and improving practises in the case company. This thesis is conducted as a qualitative research utilizing a literature review and a single case study. The literature review is utilized to form the theoretical foundation for the thesis, and to answer the first research question, providing the state of previous literature. The case study is utilized to obtain the current state in the case company, which answers the second research question. Case study data includes documentary data, observations, and interviews. Three semi-structured interviews were conducted, and the observations were obtained with participatory observing. The third research question is answered by comparing the empirical study and literature to provide improvement recommendations to the case company. The findings of this study include the empirical results of operational risk management in a single case example, as well as the proposed improvements for the case company. The empirical observations are described in detail, and guidance for future studies is given. The development proposals are directly applicable to the case company and are expected to result in a higher operational risk management capability. The literature review and empirical observations may be useful to other researchers or organizations, but the recommendations have limited generalizability outside the case company. However, some of the recommendations might be applicable to a company with similar practises or organizational context.Operatiivisten riskien hallinta korkean vaihtuvuuden ja matalan volyymin tuotantoympäristöissä. Tiivistelmä. Tämän diplomityön tavoitteena on tutkia operatiivisten riskien hallintaa korkean vaihtuvuuden ja matalan volyymin (High-Mix, Low-Volume) tuotantoympäristöissä, pienissä ja keskisuurissa yrityksissä. Työn tavoite saavutetaan vastaamalla kolmeen tutkimuskysymykseen liittyen aiempaan kirjallisuuteen, case-yrityksen nykytilaan ja case-yrityksen toiminnan parantamiseen. Diplomityö toteutetaan laadullisena tutkimuksena, jossa hyödynnetään kirjallisuuskatsausta ja case-tutkimusta. Kirjallisuuskatsaus muodostaa tutkimuksen teoreettisen viitekehyksen ja vastaa ensimmäiseen tutkimuskysymykseen esittelemällä aiempaa tutkimusta. Case-tutkimusta hyödynnetään case-yrityksen nykytilan kuvaamiseen, mikä antaa vastauksen toiseen tutkimuskysymykseen. Case-tutkimuksen aineisto koostuu case-yrityksen riskienhallintaan liittyvistä dokumenteista, havainnoista ja haastatteluista. Tutkimuksen osana suoritettiin kolme puolistrukturoitua haastattelua ja havainnot kerättiin osallistuvalla havainnoinnilla. Kolmanteen tutkimuskysymykseen vastataan empiirisen tutkimuksen ja kirjallisuuden vertailulla, jonka tuloksena saadaan ehdotuksia case-yrityksen toiminnan parantamiseen. Tutkimuksen tuloksia ovat empiiriset havainnot yksittäisestä case-yrityksestä sekä parannusehdotukset case-yrityksen operatiivisten riskien hallintaan. Tarkkaan kuvattujen empiiristen havaintojen lisäksi työssä ohjeistetaan aiheeseen liittyvää jatkotutkimusta. Annetut parannusehdotukset ovat suoraan sovellettavissa case-yritykseen ja niiden odotetaan johtavan korkeampaan operatiivisten riskien hallinnan kyvykkyyteen. Toiset organisaatiot ja tutkimukset voivat hyötyä kirjallisuuskatsauksesta ja empiirisistä havainnoista, mutta parannusehdotuksilla on rajallinen yleistettävyys case-yrityksen ulkopuolelle. Jotkin parannusehdotukset voivat kuitenkin olla sovellettavissa yrityksiin, joilla on samankaltaisia käytänteitä tai piirteitä.

Published
2023

12. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up

Author

Colombo, N., Creutzberg, C., Amant, F., Bosse, T., González-Martín, A., Ledermann, J., Marth, C., Nout, R., Querleu, D., Mirza, M.R., Sessa, C., Abal, M., Altundag, O., van Leeuwenhoek, Antoni, Banerjee, S., Casado, A., de Agustín, L.C., Cibula, D., del Campo, J.-M., Emons, G., Goffin, F., Greggi, S., Haie-Meder, C., Katsaros, D., Kesic, V., Kurzeder, C., Lax, S., Lécuru, F., Levy, T., Lorusso, D., Mäenpää, J., Matias-Guiu, X., Morice, P., Nijman, H.W., Powell, M., Reed, N., Rodolakis, A., Salvesen, H., Sehouli, J., Taylor, A., Westermann, A., and Zeimet, A.G.

Published
2016
Full Text
View/download PDF

13. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

Author

Ray-Coquard, I, Leary, A, Pignata, S, Cropet, C, González-Martin, A, Marth, C, Nagao, S, Vergote, I, Colombo, N, Mäenpää, J, Selle, F, Sehouli, J, Lorusso, D, Alia, E, Bogner, G, Yoshida, H, Lefeuvre-Plesse, C, Buderath, P, Mosconi, A, Lortholary, A, Burges, A, Medioni, J, El-Balat, A, Rodrigues, M, Park-Simon, T, Dubot, C, Denschlag, D, You, B, Pujade-Lauraine, E, Harter, P, Alia, E M Guerra, Mosconi, A M, Park-Simon, T-W, Ray-Coquard, I, Leary, A, Pignata, S, Cropet, C, González-Martin, A, Marth, C, Nagao, S, Vergote, I, Colombo, N, Mäenpää, J, Selle, F, Sehouli, J, Lorusso, D, Alia, E, Bogner, G, Yoshida, H, Lefeuvre-Plesse, C, Buderath, P, Mosconi, A, Lortholary, A, Burges, A, Medioni, J, El-Balat, A, Rodrigues, M, Park-Simon, T, Dubot, C, Denschlag, D, You, B, Pujade-Lauraine, E, Harter, P, Alia, E M Guerra, Mosconi, A M, and Park-Simon, T-W

Abstract

Background: In the PAOLA-1/ENGOT-ov25 primary analysis, maintenance olaparib plus bevacizumab demonstrated a significant progression-free survival (PFS) benefit in newly diagnosed advanced ovarian cancer patients in clinical response after first-line platinum-based chemotherapy plus bevacizumab, irrespective of surgical status. Prespecified, exploratory analyses by molecular biomarker status showed substantial benefit in patients with a BRCA1/BRCA2 mutation (BRCAm) or homologous recombination deficiency (HRD; BRCAm and/or genomic instability). We report the prespecified final overall survival (OS) analysis, including analyses by HRD status. Patients and methods: Patients were randomized 2 : 1 to olaparib (300 mg twice daily; up to 24 months) plus bevacizumab (15 mg/kg every 3 weeks; 15 months total) or placebo plus bevacizumab. Analysis of OS, a key secondary endpoint in hierarchical testing, was planned for ∼60% maturity or 3 years after the primary analysis. Results: After median follow-up of 61.7 and 61.9 months in the olaparib and placebo arms, respectively, median OS was 56.5 versus 51.6 months in the intention-to-treat population [hazard ratio (HR) 0.92, 95% confidence interval (CI) 0.76-1.12; P = 0.4118]. Subsequent poly(ADP-ribose) polymerase inhibitor therapy was received by 105 (19.6%) olaparib patients versus 123 (45.7%) placebo patients. In the HRD-positive population, OS was longer with olaparib plus bevacizumab (HR 0.62, 95% CI 0.45-0.85; 5-year OS rate, 65.5% versus 48.4%); at 5 years, updated PFS also showed a higher proportion of olaparib plus bevacizumab patients without relapse (HR 0.41, 95% CI 0.32-0.54; 5-year PFS rate, 46.1% versus 19.2%). Myelodysplastic syndrome, acute myeloid leukemia, aplastic anemia, and new primary malignancy incidence remained low and balanced between arms. Conclusions: Olaparib plus bevacizumab provided clinically meaningful OS improvement for first-line patients with HRD-positive ovarian cancer. These prespecified expl

Published
2023

14. INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

Author

Colombo, N, Gadducci, A, Sehouli, J, Rulli, E, Mäenpää, J, Sessa, C, Montes, A, Ottevanger, N, Berger, R, Vergote, I, D'Incalci, M, Churruca Galaz, C, Chekerov, R, Nyvang, G, Riniker, S, Herbertson, R, Fossati, R, Barretina-Ginesta, M, Deryal, M, Mirza, M, Biagioli, E, Iglesias, M, Funari, G, Romeo, M, Tasca, G, Pardo, B, Tognon, G, Rubio-Pérez, M, Decensi, A, De Giorgi, U, Zola, P, Benedetti Panici, P, Aglietta, M, Arcangeli, V, Zamagni, C, Bologna, A, Westermann, A, Heinzelmann-Schwarz, V, Tsibulak, I, Wimberger, P, Poveda, A, Ottevanger, N B, Nyvang, G B, Barretina-Ginesta, M P, Mirza, M R, Rubio-Pérez, M J, DeCensi, A, Colombo, N, Gadducci, A, Sehouli, J, Rulli, E, Mäenpää, J, Sessa, C, Montes, A, Ottevanger, N, Berger, R, Vergote, I, D'Incalci, M, Churruca Galaz, C, Chekerov, R, Nyvang, G, Riniker, S, Herbertson, R, Fossati, R, Barretina-Ginesta, M, Deryal, M, Mirza, M, Biagioli, E, Iglesias, M, Funari, G, Romeo, M, Tasca, G, Pardo, B, Tognon, G, Rubio-Pérez, M, Decensi, A, De Giorgi, U, Zola, P, Benedetti Panici, P, Aglietta, M, Arcangeli, V, Zamagni, C, Bologna, A, Westermann, A, Heinzelmann-Schwarz, V, Tsibulak, I, Wimberger, P, Poveda, A, Ottevanger, N B, Nyvang, G B, Barretina-Ginesta, M P, Mirza, M R, Rubio-Pérez, M J, and DeCensi, A

Abstract

BACKGROUND: This trial investigated the hypothesis that the treatment with trabectedin/PLD (TP) to extend the platinum-free interval (TFIp) can improve overall survival (OS) in patients with recurrent ovarian cancer (OC). METHODS: Patients with OC (up to two previous platinum-based lines), with a TFIp of 6-12 months, were randomised to receive carboplatin/PLD (CP) or TP followed by platinum therapy at relapse. The primary endpoint was OS (HR: 0.75). RESULTS: The study enrolled 617 patients. The median TFIp was 8.3 months and 30.3% of patients had received two previous platinum lines. 74% and 73.9% of patients, respectively, received a subsequent therapy (ST) in the CP and TP arm; in the latter TP arm 87.2% of ST was platinum-based, as per protocol. The median OS was 21.4 for CP and 21.9 months for TP (HR 1.13; 95% CI: 0.94-1.35; p = 0.197). Grade 3-5 adverse reactions occurred in 37.1% of patients in the CP arm and 69.7% of patients in the TP arm, and the most frequent were neutropenia (22.8% CP, 39.5% TP), gastrointestinal (7.1% CP, 17.4% TP), hepatic (0.7% CP, 19.1% TP). CONCLUSIONS: This study did not meet the primary endpoint. CP combination remains the standard for patients with recurrent OC and a 6-12 months TFIp; TP is an effective treatment in patients suffering from persistent platinum toxicities. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, number NCT01379989.

Published
2023

15. 39MO Clinical evaluation of a low-coverage whole-genome test for homologous recombination deficiency detection in ovarian cancer

Author

Boidot, R., primary, Blum, M.G.B., additional, Wissler, M-P., additional, Gottin, C., additional, Ruzicka, J., additional, Duforet-Frebourg, N., additional, Jeanniard, A., additional, Just, P-A., additional, Harter, P., additional, Pignata, S., additional, Gonzalez Martin, A.J., additional, Marth, C., additional, Mäenpää, J., additional, Colombo, N., additional, Vergote, I.B., additional, Fujiwara, K., additional, Bertrand, D., additional, Philippe, N., additional, Ray-Coquard, I.L., additional, and Pujade-Lauraine, E., additional

Published
2023
Full Text
View/download PDF

20. Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050/GOG 3015/ENGOT-OV39)

Author

Taşkıran, Çağatay (ORCID 0000-0002-0936-552X & YÖK ID 134190), Moore, K. N.; Bookman, M.; Sehouli, J.; Miller, A.; Anderson, C.; Scambia, G.; Myers, T.; Robison, K.; Mäenpää, J.; Willmott, L.; Colombo, N.; Thomes-Pepin, J.; Liontos, M.; Gold, M. A.; Garcia, Y.; Sharma, S. K.; Darus, C. J.; Aghajanian, C.; Okamoto, A.; Wu, X.; Safin, R.; Wu, F.; Molinero, L.; Maiya, V.; Khor, V. K.; Lin, Y. G.; Pignata, S., Taşkıran, Çağatay (ORCID 0000-0002-0936-552X & YÖK ID 134190), and Moore, K. N.; Bookman, M.; Sehouli, J.; Miller, A.; Anderson, C.; Scambia, G.; Myers, T.; Robison, K.; Mäenpää, J.; Willmott, L.; Colombo, N.; Thomes-Pepin, J.; Liontos, M.; Gold, M. A.; Garcia, Y.; Sharma, S. K.; Darus, C. J.; Aghajanian, C.; Okamoto, A.; Wu, X.; Safin, R.; Wu, F.; Molinero, L.; Maiya, V.; Khor, V. K.; Lin, Y. G.; Pignata, S.

Abstract

Purpose: to evaluate the addition of the humanized monoclonal antiprogrammed death ligand-1 (PD-L1) antibody, atezolizumab, to platinum-based chemotherapy and bevacizumab in newly diagnosed stage III or IV ovarian cancer (OC). Methods: this multicenter placebo-controlled double-blind randomized phase III trial (ClinicalTrials.gov identifier: NCT03038100) enrolled patients with newly diagnosed untreated International Federation of Gynecology and Obstetrics (FIGO) stage III or IV OC who either had undergone primary cytoreductive surgery with macroscopic residual disease or were planned to receive neoadjuvant chemotherapy and interval surgery. Patients were stratified by FIGO stage, Eastern Cooperative Oncology Group performance status, tumor immune cell PD-L1 staining, and treatment strategy and randomly assigned 1:1 to receive 3-weekly cycles of atezolizumab 1,200 mg or placebo (day 1, cycles 1-22), with paclitaxel plus carboplatin (day 1, cycles 1-6) plus bevacizumab 15 mg/kg (day 1, cycles 2-22), omitting perioperative bevacizumab in neoadjuvant patients. The co-primary end points were investigator-assessed progression-free survival and overall survival in the intention-to-treat and PD-L1-positive populations. Results: between March 8, 2017, and March 26, 2019, 1,301 patients were enrolled. The median progression-free survival was 19.5 versus 18.4 months with atezolizumab versus placebo, respectively (hazard ratio, 0.92; 95% CI, 0.79 to 1.07; stratified log-rank P = .28), in the intention-to-treat population and 20.8 versus 18.5 months, respectively (hazard ratio, 0.80; 95% CI, 0.65 to 0.99; P = .038), in the PD-L1-positive population. The interim (immature) overall survival results showed no significant benefit from atezolizumab. The most common grade 3 or 4 adverse events were neutropenia (21% with atezolizumab v 21% with placebo), hypertension (18% v 20%, respectively), and anemia (12% v 12%). Conclusion: current evidence does not support the use of immune check

Published
2021

23. Safety, Tolerability and Pharmacokinetics (PK) of AZD8154, A Selective PI3Kγδ Inhibitor, After Single and Multiple Ascending Inhaled Doses in Healthy Volunteers

Author

Asimus, S., primary, Sadiq, W.M., additional, Kristensson, C., additional, Hagberg, A., additional, Mäenpää, J., additional, Fuhr, R., additional, Koernicke, T., additional, Necander, S., additional, Jellesmark Jensen, T., additional, Nemes, S., additional, Keen, C., additional, Brailsford, W., additional, and Betts, J., additional

Published
2020
Full Text
View/download PDF

28. Natural history of preclinical IDDM in high risk siblings

Author

Knip, M., Vähäsalo, P., Karjalainen, J., Lounamaa, R., Åkerblom, H. K., Tuomilehto, J., Toivanen, L., Virtala, E., Pitkäniemi, J., Fagerlund, A., Flittner, M., Gustafsson, B., Häggquist, C., Hakulinen, A., Herva, L., Hiltunen, P., Huhtamäki, T., Huttunen, N. -P., Huupponen, T., Hyttinen, M., Joki, T., Jokisalo, R., Käär, M. -L., Kallio, S., Kaprio, E. A., Kaski, U., Laine, L., Lappalainen, J., Mäenpää, J., Mäkelä, A. -L., Niemi, K., Niiranen, A., Nuuja, A., Ojajärvi, P., Otonkoski, T., Pihlajamäki, K., Pöntynen, S., Rajantie, J., Sankala, J., Schumacher, J., Sillanpää, M., Ståhlberg, M. -R., Stråhlmann, C. -H., Uotila, T., Väre, M., Varimo, P., Wetterstrand, G., Aro, A., Hurme, H., Höyty, H., Ilonen, J., Leinikki, P., Miettinen, A., Räsänen, L., Reunanen, A., Savilahti, E., Tuomilehto-Wolf, E., and Virtanen, S. M.

Published
1994
Full Text
View/download PDF

29. Diet, cow's milk protein antibodies and the risk of IDDM in Finnish children

Author

Virtanen, S. M., Saukkonen, T., Savilahti, E., Ylönen, K., Räsänen, L., Aro, A., Knip, M., Tuomilehto, J., Åkerblom, H. K., Lounamaa, R., Toivanen, L., Kaprio, E. A., Pitkäniemi, J., Virtala, E., Fagerlund, A., Flittner, M. v., Gustafsson, B., Häggqvist, C., Hakulinen, A., Herva, L., Hiltunen, P., Huhtamäki, T., Huttunen, N. -P., Huupponen, T., Hyttinen, M., Joki, T., Jokisalo, R., Käär, M. -L., Kallio, S., Kaski, U., Laine, L., Lappalainen, J., Mäenpää, J., Mäkelä, A. -L., Niemi, K., Niiranen, A., Ojajärvi, P., Otonkoski, T., Pihlajamäki, K., Pöntynen, S., Rajantie, J., Sankala, J., Schumacher, J., Sillanpää, M., Ståhlberg, M. -R., Stråhlmann, C. -H., Uotila, T., Väre, M., and Varimo, P.

Published
1994
Full Text
View/download PDF

30. Decline of mumps antibodies in Type 1 (insulin-dependent) diabetic children and a plateau in the rising incidence of Type 1 diabetes after introduction of the mumps-measles-rubella vaccine in Finland

Author

Hyöty, H., Hiltunen, M., Reunanen, A., Leinikki, P., Vesikari, T., Lounamaa, R., Tuomilehto, J., Åkerblom, H. K., Toivanen, L., Kaprio, E. A., Fagerlund, A., Flittner, M., Gustafsson, B., Häggqvist, C., Hakulinen, A., Herva, L., Hiltunen, P., Huhtamäki, T., Huttunen, N. -P., Huupponen, T., Hyttinen, M., Joki, T., Jokisalo, R., Käär, M. -L., Kallio, S., Kaski, U., Knip, M., Laine, L., Lappalainen, J., Mäenpää, J., Mäkelä, A. -L., Niemi, K., Niiranen, A., Nuuja, A., Ojajärvi, P., Otonkoski, T., Pihlajamäki, K., Pöntynen, S., Rajantie, J., Sankala, J., Schumacher, J., Sillanpää, M., Ståhlberg, M. -R., Stråhlmann, C. -H., Uotila, T., Väre, M., Varimo, P., Wettenstrand, G., and the Childhoood Diabetes in Finland Study Group

Published
1993
Full Text
View/download PDF

31. HLA haplotypes in Type 1 (insulin-dependent) diabetes mellitus: molecular analysis of the HLA-DQ locus

Author

Tienari, P. J., Tuomilehto-Wolf, E., Tuomilehto, J., Peltonen, L., Åkerblom, H. K., Fagerlund, A., Flittner, M., Gustafsson, B., Hakulinen, A., Herva, L., Hiltunen, P., Huhtamäki, T., Huttunen, N. P., Huupponen, T., Hyttinen, M., Häggqvist, Ch., Joki, T., Jokisalo, R., Kallio, S., Kaprio, E. A., Kaski, U., Knip, M., Käär, M. L., Laine, L., Lappalainen, J., Mäenpää, J., Mäkelä, A. L., Niemi, K., Niiranen, A., Ojajärvi, P., Otonkoski, T., Pihlajamäki, K., Pöntynen, S., Sankala, J., Schumacher, J., Sillanpää, M., Stråhlmann, C. H., Ståhlberg, M. R., Uotila, T., Varimo, P., and Väre, M.

Published
1992
Full Text
View/download PDF

32. Epidemiology of childhood diabetes mellitus in Finland — background of a nationwide study of Type 1 (insulin-dependent) diabetes mellitus

Author

Tuomilehto, J., Lounamaa, R., Tuomilehto-Wolf, E., Reunanen, A., Virtala, E., Kaprio, E. A., Åkerblom, H. K., Toivanen, L., Fagerlund, A., Flittner, M., Gustafsson, B., Hakulinen, A., Herva, L., Hiltunen, P., Huhtamäki, T., Huttunen, N. -P., Huupponen, T., Hyttinen, M., Häggqvist, C., Joki, T., Jokisalo, R., Kallio, S., Kaski, U., Knip, M., Käär, M. -L., Laine, L., Lappalainen, J., Mäenpää, J., Mäkelä, A. -L., Niemi, K., Niiranen, A., Nuuja, A., Ojajärvi, P., Otonkoski, T., Pihlajamäki, K., Pöntynen, S., Ranjantie, J., Sankala, J., Schumacher, J., Sillanpää, M., Stråhlmann, C. -H., Ståhlberg, M. -R., Uotila, T., Varimo, P., Wetterstrand, G., Väre, M., Aro, A., Hurme, H., Hyöty, H., Ilonen, J., Karjalainen, J., LaPorte, R., Leinikki, P., Miettinen, A., Räsänen, L., Savilahti, E., and Virtanen, S. M.

Published
1992
Full Text
View/download PDF

35. Tumor cell-specific Serpin A1 expression in vulvar squamous cell carcinoma

Author

Lagerstedt, M, Huotari-Orava, R, Nyberg, R, Nissinen, L, Farshchian, M, Laasanen, S-L, Snellman, E, Mäenpää, J, Kähäri, V-M, Lääketieteen ja terveysteknologian tiedekunta - Faculty of Medicine and Health Technology, and Tampere University

Subjects
Vulvar squamous cell carcinoma, p53, p16, Naisten- ja lastentaudit - Gynaecology and paediatrics, Serpin A1, Lichen sclerosus
Published
2019

36. Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev

Author

Fujiwara, K., primary, Harter, P., additional, Leary, A., additional, Perol, D., additional, Pignata, S., additional, González-Martín, A., additional, Petru, E., additional, van Nieuwenhuysen, E., additional, Colombo, N., additional, Mäenpää, J., additional, Selle, F., additional, de Gregorio, N., additional, Lorusso, D., additional, Guerra Alia, E.M., additional, Lefeuvre-Plesse, C., additional, Buderath, P., additional, Lortholary, A., additional, Burges, A., additional, Pujade-Lauraine, E., additional, and Ray-Coquard, I.L., additional

Published
2019
Full Text
View/download PDF

37. Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab

Author

Harter, P, primary, Mouret-Reynier, MA, additional, Pignata, S, additional, Cropet, C, additional, González-Martin, A, additional, Bogner, G, additional, Fujiwara, K, additional, Vergote, I, additional, Colombo, N, additional, Mäenpää, J, additional, Floquet, A, additional, El-Balat, A, additional, Lorusso, D, additional, Guerra Alia, EM, additional, Fabbro, M, additional, Schmalfeldt, B, additional, Hardy Blessard, AC, additional, Runnebaum, I, additional, Pujade-Lauraine, E, additional, and Ray-Coquard, I, additional

Published
2019
Full Text
View/download PDF

38. Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev

Author

Ray-Coquard, I.L., primary, Pautier, P., additional, Pignata, S., additional, Pérol, D., additional, González-Martín, A., additional, Sevelda, P., additional, Fujiwara, K., additional, Vergote, I.B., additional, Colombo, N., additional, Mäenpää, J., additional, Selle, F., additional, Sehouli, J., additional, Lorusso, D., additional, Alia, E M Guerra, additional, Lefeuvre-Plesse, C., additional, Canzler, U., additional, Lortholary, A., additional, Marmé, F., additional, Pujade-Lauraine, E., additional, and Harter, P., additional

Published
2019
Full Text
View/download PDF

42. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

Author

Ray-Coquard, I, Pautier, P, Pignata, S, Pérol, D, González-Martín, A, Berger, R, Fujiwara, K, Vergote, I, Colombo, N, Mäenpää, J, Selle, F, Sehouli, J, Lorusso, D, Guerra Alía, E, Reinthaller, A, Nagao, S, Lefeuvre-Plesse, C, Canzler, U, Scambia, G, Lortholary, A, Marmé, F, Combe, P, de Gregorio, N, Rodrigues, M, Buderath, P, Dubot, C, Burges, A, You, B, Pujade-Lauraine, E, Harter, P, Ray-Coquard, Isabelle, Pautier, Patricia, Pignata, Sandro, Pérol, David, González-Martín, Antonio, Berger, Regina, Fujiwara, Keiichi, Vergote, Ignace, Colombo, Nicoletta, Mäenpää, Johanna, Selle, Frédéric, Sehouli, Jalid, Lorusso, Domenica, Guerra Alía, Eva M, Reinthaller, Alexander, Nagao, Shoji, Lefeuvre-Plesse, Claudia, Canzler, Ulrich, Scambia, Giovanni, Lortholary, Alain, Marmé, Frederik, Combe, Pierre, de Gregorio, Nikolaus, Rodrigues, Manuel, Buderath, Paul, Dubot, Coraline, Burges, Alexander, You, Benoît, Pujade-Lauraine, Eric, Harter, Philipp, Ray-Coquard, I, Pautier, P, Pignata, S, Pérol, D, González-Martín, A, Berger, R, Fujiwara, K, Vergote, I, Colombo, N, Mäenpää, J, Selle, F, Sehouli, J, Lorusso, D, Guerra Alía, E, Reinthaller, A, Nagao, S, Lefeuvre-Plesse, C, Canzler, U, Scambia, G, Lortholary, A, Marmé, F, Combe, P, de Gregorio, N, Rodrigues, M, Buderath, P, Dubot, C, Burges, A, You, B, Pujade-Lauraine, E, Harter, P, Ray-Coquard, Isabelle, Pautier, Patricia, Pignata, Sandro, Pérol, David, González-Martín, Antonio, Berger, Regina, Fujiwara, Keiichi, Vergote, Ignace, Colombo, Nicoletta, Mäenpää, Johanna, Selle, Frédéric, Sehouli, Jalid, Lorusso, Domenica, Guerra Alía, Eva M, Reinthaller, Alexander, Nagao, Shoji, Lefeuvre-Plesse, Claudia, Canzler, Ulrich, Scambia, Giovanni, Lortholary, Alain, Marmé, Frederik, Combe, Pierre, de Gregorio, Nikolaus, Rodrigues, Manuel, Buderath, Paul, Dubot, Coraline, Burges, Alexander, You, Benoît, Pujade-Lauraine, Eric, and Harter, Philipp

Abstract

BACKGROUND: Olaparib has shown significant clinical benefit as maintenance therapy in women with newly diagnosed advanced ovarian cancer with a BRCA mutation. The effect of combining maintenance olaparib and bevacizumab in patients regardless of BRCA mutation status is unknown. METHODS: We conducted a randomized, double-blind, international phase 3 trial. Eligible patients had newly diagnosed, advanced, high-grade ovarian cancer and were having a response after first-line platinum-taxane chemotherapy plus bevacizumab. Patients were eligible regardless of surgical outcome or BRCA mutation status. Patients were randomly assigned in a 2:1 ratio to receive olaparib tablets (300 mg twice daily) or placebo for up to 24 months; all the patients received bevacizumab at a dose of 15 mg per kilogram of body weight every 3 weeks for up to 15 months in total. The primary end point was the time from randomization until investigator-assessed disease progression or death. RESULTS: Of the 806 patients who underwent randomization, 537 were assigned to receive olaparib and 269 to receive placebo. After a median follow-up of 22.9 months, the median progression-free survival was 22.1 months with olaparib plus bevacizumab and 16.6 months with placebo plus bevacizumab (hazard ratio for disease progression or death, 0.59; 95% confidence interval [CI], 0.49 to 0.72; P<0.001). The hazard ratio (olaparib group vs. placebo group) for disease progression or death was 0.33 (95% CI, 0.25 to 0.45) in patients with tumors positive for homologous-recombination deficiency (HRD), including tumors that had BRCA mutations (median progression-free survival, 37.2 vs. 17.7 months), and 0.43 (95% CI, 0.28 to 0.66) in patients with HRD-positive tumors that did not have BRCA mutations (median progression-free survival, 28.1 vs. 16.6 months). Adverse events were consistent with the established safety profiles of olaparib and bevacizumab. CONCLUSIONS: In patients with advanced ovarian cancer receiving first-li

Published
2019

44. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up

Author

Colombo, N. Creutzberg, C. Amant, F. Bosse, T. González-Martón, A. Ledermann, J. Marth, C. Nout, R. Querleu, D. Mirza, M.R. Sessa, C. Abal, M. Altundag, O. Banerjee, S. Casado, A. De Agustín, L.C. Cibula, D. Del Campo, J.-M. Emons, G. Goffin, F. González-Martín, A. Greggi, S. Haie-Meder, C. Katsaros, D. Kesic, V. Kurzeder, C. Lax, S. Lécuru, F. Levy, T. Lorusso, D. Mäenpää, J. Matias-Guiu, X. Morice, P. Nijman, H.W. Powell, M. Reed, N. Rodolakis, A. Salvesen, H. Sehouli, J. Taylor, A. Westermann, A. Zeimet, A.G. The ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group

Abstract

The first joint European Society for Medical Oncology (ESMO), European SocieTy for Radiotherapy & Oncology (ESTRO) and European Society of Gynaecological Oncology (ESGO) consensus conference on endometrial cancer was held on 11-13 December 2014 in Milan, Italy, and comprised a multidisciplinary panel of 40 leading experts in the management of endometrial cancer. Before the conference, the expert panel prepared three clinically relevant questions about endometrial cancer relating to the following four areas: prevention and screening, surgery, adjuvant treatment and advanced and recurrent disease. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the consensus conference, the panel developed recommendations for each specific question and a consensus was reached. Results of this consensus conference, together with a summary of evidence supporting each recommendation, are detailed in this article. All participants have approved this final article. © The Author 2015.

Published
2016

46. A phase 1 study to evaluate the safety and tolerability of bevacizumab-niraparib combination therapy and determine the recommended phase 2 dose (RP2D) in women with platinum-sensitive epithelial ovarian cancer (ENGOT-OV24/AVANOVA1)

Author

Mirza, M.R., primary, Wang, J., additional, Mau-Sørensen, M., additional, Birrer, M.J., additional, Wang, X., additional, Jørgensen, M., additional, Zhang, Z-Y., additional, Roed, H., additional, Malander, S., additional, Nielsen, F., additional, Bjørge, L., additional, Lassen, U., additional, Boufercha, L., additional, Brøsen, K., additional, Kansra, V., additional, and Mäenpää, J., additional

Published
2017
Full Text
View/download PDF

47. BRCA1&2 tumoral and germline status for ovarian cancer patients in first line setting within the PAOLA-01 trial

Author

Callens, C., primary, Vaur, D., additional, Soubeyran, I., additional, Rouleau, E., additional, Just, P-A., additional, Guillerm, E., additional, Golmard, L., additional, Goardon, N., additional, Sevenet, N., additional, Cabaret, O., additional, Harter, P., additional, Gonzalez Martin, A., additional, Fujiwara, K., additional, Pignata, S., additional, Colombo, N., additional, Marth, C., additional, Vergote, I., additional, Mäenpää, J., additional, Pujade-Lauraine, E., additional, and Ray-Coquard, I., additional

Published
2017
Full Text
View/download PDF

48. LBA10 - Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev

Author

Fujiwara, K., Harter, P., Leary, A., Perol, D., Pignata, S., González-Martín, A., Petru, E., van Nieuwenhuysen, E., Colombo, N., Mäenpää, J., Selle, F., de Gregorio, N., Lorusso, D., Guerra Alia, E.M., Lefeuvre-Plesse, C., Buderath, P., Lortholary, A., Burges, A., Pujade-Lauraine, E., and Ray-Coquard, I.L.

Published
2019
Full Text
View/download PDF

49. LBA2_PR - Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev

Author

Ray-Coquard, I.L., Pautier, P., Pignata, S., Pérol, D., González-Martín, A., Sevelda, P., Fujiwara, K., Vergote, I.B., Colombo, N., Mäenpää, J., Selle, F., Sehouli, J., Lorusso, D., Alia, E M Guerra, Lefeuvre-Plesse, C., Canzler, U., Lortholary, A., Marmé, F., Pujade-Lauraine, E., and Harter, P.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results